No analyst coverage available for this stock.
PainChek Limited is a healthcare technology company specializing in the development and commercialization of innovative medical device applications for pain assessment. Its flagship product, PainChek, leverages artificial intelligence and facial recognition technology through smartphones and tablets to objectively detect and evaluate pain in individuals who cannot reliably communicate their discomfort, such as those with dementia, cognitive impairments, disabilities, or pre-verbal infants. The technology supports care providers across sectors including aged care, disability services, home care, hospitals, and infant care, promoting best-practice pain management and better clinical outcomes. PainChek is clinically validated and holds regulatory clearances in multiple jurisdictions, including Australia, New Zealand, Canada, the UK, the European Union, Singapore, and Malaysia. With millions of assessments conducted globally, PainChek Limited enables more accurate, efficient pain monitoring and integrates seamlessly with leading health care management systems, reducing reliance on subjective or paper-based tools. The company’s solutions address a significant gap in healthcare, giving a voice to vulnerable populations and helping caregivers make more informed treatment decisions, thus enhancing the quality of care on an international scale.